CAR-TCR Summit Europe 2021 | How the TCR field can learn from CARs

Dolores J. Schendel, PhD, Medigene, Planegg, Germany, provides an overview of how the field of T-cell receptor (TCR) therapy research has evolved in recent years and continues to benefit and learn from challenges already faced in the chimeric antigen receptor (CAR) field in terms of logistics, infrastructure and regulation. She also discusses the potential TCR therapies have in targeting solid tumors and how TCR engineering and their use in combination therapies could lead to significant advances in the future. This interview took place during the CAR-TCR Summit Europe 2021.